Doctors at the Oklahoma Medical Research Foundation are celebrating what could become a breakthrough in brain cancer treatment.
The Oklahoma Medical Research Foundation is one step closer to beating rare forms of brain cancers.
The drug treats fast-growing, deadly brain cancers with no effective treatment.
In a new study, the OMRF compound OKN-007 is being combined with the current standard-of-care medication for glioblastoma.
Oblato, Inc., has acquired all rights from OMRF to OKN-007, an investigational drug for the treatment of a deadly form of brain cancer.
As Mike Schuster nears the three-year anniversary of his diagnosis with glioblastoma, he’s already doubled the life expectancy for patients with the deadly cancer.